{'fraction_non_alphanumeric': 0.01518288474810214, 'fraction_numerical': 0.00759144237405107, 'mean_word_length': 5.839622641509434, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparison of safety, efficacy and serum immune indexes of Clostridium butyricum Enterococcus triple viable vs Bifidobacterium triple viable in the treatment of bronchial asthma in children.

The principal objective of our study was to investigate the safety and efficacy of Clostridium butyricum enterococci triple viable vs Bifidobacterium triple viable in the cure of bronchial asthma in children, and to compare the serum immune indexes. We retrospectively investigated 180 children with BA treated in Lianshui County People's Hospital from June 2019 to June 2021. These children were divided into three groups in accordance with the cure methods: The control group (group A) gave consent to routine drug treatment, the children in the Clostridium butyricum enterococci triple viable group (group B) received routine treatment, combined with Clostridium butyricum enterococci triple viable tablets and the children in the Bifidobacterium Lactobacillus triple viable group (group C) received routine treatment, combined with Bifidobacterium Lactobacillus triple viable powder. Combined with the treatment results, the effect of combined probiotics on BA in children is more significant than that of routine treatment, which can effectively enhance the immune function, lung function and inflammation of children. The effect of Clostridium butyricum enterococci triple viable bacteria is better than that of Bifidobacterium triple viable bacteria.